MedPal AI float on AIM
August 2025
MedPal is a UK-based digital health and AI company focused on wellness management founded in 2021
The Company’s core product is a non-clinical digital health app that aggregates and monitors users’ health metrics and provides wellness guidance.
The MedPal app can connect to over 100 fitness apps and wearables on Apple iOS and Google Android operating systems, aggregating an individual’s health data into one unified profile. The Company uses AI to provide wellbeing monitoring, lifestyle advice, and bio-hacks based on real-time data. Its goal is to use conversational AI to take wellness assistance to the next level and aims to be one of the first voice health agents to interact with users in conversational AI, aiming to achieve human-like levels of interaction and translating raw data into meaningful insights, fitness and wellbeing alerts. It also aims to be able to notify users to check on their wellbeing, recommend bio-hacks, and detect risks in real-time.
Placing and Admission to trading on AIM
On 26th August 2025 admission and the first day of dealings commenced by way of a Placing of 40,985,000 new Ordinary Shares at 4 pence per share and Retail Offer of up to 9,015,000 new Ordinary Shares at 4 pence per share.
The Perivan shareholder communications team was delighted to work with Cairn Financial LLP who acted as Nominated Adviser to MedPal on the successful production and publication of the 103-page admission document which included the provision of the Engage data room platform which was utilised for the secure proof distribution.
For further information, click here.
Perivan is the market leader for IPO admission document production and specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.
